TY - JOUR
TI - Cardiovascular disease in women: Executive summary of the expert panel statement of women in cardiology of the hellenic cardiological society
AU - Chrysohoou, C.
AU - Aggeli, C.
AU - Avgeropoulou, C.
AU - Aroni, M.
AU - Bonou, M.
AU - Boutsikou, M.
AU - Brili, S.
AU - Chamodraka, E.
AU - Dagre, A.
AU - Flevari, P.
AU - Fountoulaki, A.
AU - Frogoudaki, A.
AU - Gkouziouta, A.
AU - Grapsa, J.
AU - Hatzinikolaou-Kotsakou, E.
AU - Kalantzi, K.
AU - Kitsiou, A.
AU - Kostakou, P.
AU - Kourea, R.
AU - Koutrolou-Sotiropoulou, P.
AU - Marketou, M.
AU - Mavrogeni, S.
AU - Naka, K.K.
AU - Nikolaou, M.
AU - Papazachou, O.
AU - Papavasileiou, L.P.
AU - Simeonidou, E.
AU - Theopistou, A.
AU - Triantafyllidi, H.
AU - Trikka, C.
AU - Tsekoura, D.
AU - Tzifa, A.
AU - Vaina, S.
AU - Vrettou, A.R.
AU - Zaglavara, T.
AU - Kolovou, G.
AU - Aggelopoulou, E.
AU - Antoniou, A.
AU - Bistola, V.
AU - Bilianou, E.
AU - Boufidou, A.
AU - Demerouti, E.
AU - Giannakopoulou, V.
AU - Karvouni, E.
AU - Komnou, A.
AU - Kyriakou, P.
AU - Limperi, S.
AU - Mavrogianni, A.
AU - Michalopoulou, H.
AU - Nakou, E.
AU - Nyhtari, E.
AU - Papavasiliou, M.
AU - Pietri, P.
AU - Petropoulou, E.
AU - Prappa, E.
AU - Riga, M.
AU - Sbarouni, E.
AU - Stavrati, A.
AU - Reviewers
JO - Ελληνική καρδιολογική επιθεώρηση
PY - 2020
VL - 61
TODO - 6
SP - 362-377
PB - Hellenic Cardiological Society
SN - 1011-7970
TODO - 10.1016/j.hjc.2020.09.015
TODO - acetylsalicylic acid;  angiotensin 1 receptor;  angiotensin 2 receptor;  antithrombocytic agent;  autoantibody;  carvedilol;  cathepsin D;  cholesterol;  chymase;  contraceptive agent;  dipeptidyl carboxypeptidase;  estrogen;  glucose;  heparin;  high density lipoprotein;  histamine;  hydroxymethylglutaryl coenzyme A reductase inhibitor;  metoprolol;  nebivolol;  nitric oxide;  progesterone;  propranolol;  renin;  testosterone;  trastuzumab;  triacylglycerol;  troponin I;  tryptase, aortic dissection;  aortic valve disease;  aortic valve stenosis;  artery embolism;  atherosclerosis;  bicuspid aortic valve;  breast cancer;  cardiac resynchronization therapy;  cardiology;  cardiovascular disease;  cardiovascular magnetic resonance;  cardiovascular risk factor;  clinical trial (topic);  congenital heart disease;  conservative treatment;  coronary angiography;  coronary artery disease;  coronary artery dissection;  coronary flow reserve;  coronavirus disease 2019;  diabetes mellitus;  dyslipidemia;  echocardiography;  electrocardiogram;  familial hypercholesterolemia;  female;  fibrinolysis;  heart arrest;  heart arrhythmia;  heart catheterization;  heart failure;  heart failure with preserved ejection fraction;  heart infarction;  heart surgery;  hellenic cardiological society;  hormone substitution;  human;  hypertension;  hypertrophic cardiomyopathy;  Kounis syndrome;  lifestyle;  low risk population;  medical society;  microvasculature;  morbidity;  mortality;  myocardial bridging;  nuclear magnetic resonance imaging;  obesity;  ovary polycystic disease;  pathophysiology;  peripheral occlusive artery disease;  physiology;  plasma renin activity;  postmenopause;  preeclampsia;  pregnancy;  pregnancy diabetes mellitus;  prognosis;  pulmonary hypertension;  quality of life;  renin angiotensin aldosterone system;  Review;  rheumatoid arthritis;  smoking;  takotsubo cardiomyopathy;  thrombocythemia;  transient ischemic attack;  aged;  cardiovascular disease;  male;  risk factor;  secondary prevention;  women's health, Aged;  Cardiology;  Cardiovascular Diseases;  Female;  Humans;  Male;  Risk Factors;  Secondary Prevention;  Women's Health
TODO - The perception that women represent a low-risk population for cardiovascular (CV) disease (CVD) needs to be reconsidered. Starting from risk factors, women are more likely to be susceptible to unhealthy behaviors and risk factors that have different impact on CV morbidity and mortality as compared to men. Despite the large body of evidence as regards the effect of lifestyle factors on the CVD onset, the gender-specific effect of traditional and non-traditional risk factors on the prognosis of patients with already established CVD has not been well investigated and understood. Furthermore, CVD in women is often misdiagnosed, underestimated, and undertreated. Women also experience hormonal changes from adolescence till elder life that affect CV physiology. Unfortunately, in most of the clinical trials women are underrepresented, leading to the limited knowledge of CV and systemic impact effects of several treatment modalities on women's health. Thus, in this consensus, a group of female cardiologists from the Hellenic Society of Cardiology presents the special features of CVD in women: the different needs in primary and secondary prevention, as well as therapeutic strategies that may be implemented in daily clinical practice to eliminate underestimation and undertreatment of CVD in the female population. © 2020 Hellenic Society of Cardiology
ER -